Stomach cancer-derived del223V-226L mutation of the STCH gene causes loss of sensitization to TRAIL-mediated apoptosis.

Biochem Biophys Res Commun

Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Published: November 2008

AI Article Synopsis

  • The stress 70 protein chaperone (STCH), part of the HSP70 superfamily, is linked to stomach cancer susceptibility but its exact functions are not well understood.
  • A specific mutation (668del12bp) in STCH results in a deletion in its ATP-binding domain, leading to loss of ATP-binding capability.
  • The normal STCH enhances cell survival in response to TRAIL-induced cell death, while the mutated version does not, indicating STCH's role in regulating this cell death pathway.

Article Abstract

The stress 70 protein chaperone (STCH), a member of the heat shock protein 70 (HSP70) superfamily, is a microsomal protein that contains a N-terminal ATPase domain but lacks a C-terminal protein binding domain. Although cell-protective functions of HSP70 members are well characterized, the biological relevance of STCH remains unclear. We previously identified STCH as a candidate gene for susceptibility to stomach cancer by genetic analyses. In this study, we searched somatic mutations of STCH in human stomach cancer and identified the 668del12bp mutation in exon 4, resulting in a four amino acid deletion (del223V-226L) in the conserved ATP-binding domain. In vitro binding assays revealed that this mutant lacks ATP-binding activity. Overexpression of wild-type STCH sensitized cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death, whereas del223V-226L mutant did not show any effect. These results suggest that STCH has a role in cell survival via modulation of the TRAIL-mediated cell death pathway.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2008.09.013DOI Listing

Publication Analysis

Top Keywords

stomach cancer
8
cell death
8
stch
7
stomach cancer-derived
4
cancer-derived del223v-226l
4
del223v-226l mutation
4
mutation stch
4
stch gene
4
gene loss
4
loss sensitization
4

Similar Publications

Background: The COVID-19 pandemic has overloaded healthcare systems worldwide. Other diseases, such as neoplasms, including gastric cancer, remained prevalent and had their treatment compromised.

Aims: The aim of this study was to evaluate the impact of the COVID-19 pandemic on the treatment of gastric cancer and adherence to the recommended preoperative COVID-19 screening protocol.

View Article and Find Full Text PDF

[Gastric cancer cases in Brazil and waiting times for diagnosis and treatment].

Cien Saude Colet

January 2025

Departamento de Epidemiologia e Métodos Quantitativos, Escola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz. Rio de Janeiro RJ Brasil.

The aim is to describe the sociodemographic and clinical-epidemiological profile of hospital cases of gastric cancer and to analyze factors associated with the Time-to-Treatment in Brazil. Exploratory study of sociodemographic and clinical-epidemiological characteristics of cases of gastric cancer. Time-to-Treatment were continuously estimated and then categorized into ≤ 60/> 60 days to estimate prevalence.

View Article and Find Full Text PDF

Background: Gastric cancer poses a major diagnostic and therapeutic challenge. Improved visualization of tumor margins and lymph node metastases with tumor-specific fluorescent markers could improve outcomes.

Methods: To establish orthotopic models of gastric cancer, one million cells of the human gastric cancer cell line, MKN45, were suspended in 50 μl of equal parts PBS and Matrigel and injected into the nude mouse stomach with a 29-gauge needle.

View Article and Find Full Text PDF

Risks of anti- therapy and long-term therapy with antisecretory drugs.

World J Gastroenterol

January 2025

Department of Therapy, North Caucasus State Academy, Cherkessk 369000, Russia.

() infection has a protective effect on gastroesophageal reflux disease (GERD). Both of these diseases have a very high incidence and prevalence. As a result, GERD often recurs after anti- therapy.

View Article and Find Full Text PDF

Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study.

World J Surg Oncol

January 2025

Colorectal Surgery Department, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, No. 283 Tongzipo Road, Yuelu District, Changsha, Hunan, 410013, China.

Objective: The clinical benefits of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients are controversial. This study intended to evaluate the efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in these patients.

Methods: In this retrospective study, 71 locally advanced gastric cancer patients receiving neoadjuvant bevacizumab plus chemotherapy or neoadjuvant chemotherapy alone were divided into bevacizumab plus chemo group (N = 23) and chemo group (N = 48).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!